



Material adicional

Diabetes mellitus y riesgos del bloqueo dual del sistema renina-angiotensina-aldosterona

Ferrán Catalá-López^{a,b*} y Diego Macías Saint-Gerons^a

^a*División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España*

^b*Centro Superior de Investigación en Salud Pública (CSISP), Valencia, España*

Tabla 1

Referencias bibliográficas de los nueve ensayos incluidos

1. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. <i>BMJ</i> . 2000;321:1440-4.
2. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. <i>Diabetes Care</i> . 2005;28:273-7.
3. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. <i>J Renin Angiotensin Aldosterone Syst</i> . 2007;8:190-8.
4. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. <i>N Engl J Med</i> . 2008;358:2433-46.
5. Telmisartan (Micardis®). Combined clinical and statistical review. Bethesda: U.S. Food and Drug Administration; 2009 [citado 25 Abr 2012]. Disponible en: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM173536.pdf
6. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. <i>J Am Soc Nephrol</i> . 2009;20:2641-50.
7. Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. <i>Am J Cardiovasc Drugs</i> . 2011;11:327-33.
8. Titan SM, Vieira JM Jr, Dominguez WV, Barros RT, Zatz R. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. <i>Clin Nephrol</i> . 2011;76:273-83.

9. Parving HH, Brenner BM, McMurray JJ, De Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes (ALTITUDE). *N Engl J Med*. 2012 3 Nov [Epub ahead of print]. DOI: 10.1056/NEJMoa1208799.

10. FDA Drug Safety Communication: New warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Bethesda: U.S. Food and Drug Administration; 2012 [citado 22 Abr 2012]. Disponible en: <http://www.fda.gov/drugs/drugsafety/ucm300889.htm>

Tabla 2

Análisis de sensibilidad (eliminación del estudio ALTITUDE)

Variable de seguridad	Bloqueo dual frente a monoterapia, n/N	Modelo de efectos aleatorios, RR (IC95%)	Modelo de efectos fijos, RR (IC95%)	Heterogeneidad, I ²
Hiperpotasemia (6 estudios)	83/850; 59/1.127	1,63 (1,12-2,38)	1,56 (1,13-2,16)	12,1%
Hipotensión (2 estudios)	13/368; 5/428	2,86 (0,90-9,14)	2,92 (0,96-8,86)	4,6%
Daño renal (6 estudios)	83/1.058; 108/1.615	1,10 (0,68-1,76)	0,98 (0,75-1,28)	48,5%
Mortalidad (2 estudios)	54/549; 19/824	0,92 (0,52-1,65)	0,96 (0,73-1,28)	4,6%